Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Vamsi, Bollu"'
Autor:
Gilles Salles, Stephen J. Schuster, Luca Fischer, John Kuruvilla, Piers E. M. Patten, Bastian von Tresckow, Sonali Smith, Ana Jiménez Ubieto, Keith L. Davis, Saurabh Nagar, Jie Zhang, Vamsi Bollu, Etienne Jousseaume, Roberto Ramos, Yucai Wang, Brian K. Link
Publikováno v:
HemaSphere, Vol 6, Iss 7, p e745 (2022)
This study (ReCORD-FL) sought to construct a historical control cohort to augment single-arm trials in relapsed/refractory follicular lymphoma (r/r FL). A retrospective study in 10 centers across North America and Europe was conducted. Adults with gr
Externí odkaz:
https://doaj.org/article/e780703b57a547aa9be64bc3cbede090
Autor:
Hongbo, Yang, Vamsi, Bollu, Stephen, Lim, Mimi, Tesfaye, Anand A, Dalal, Angela, Lax, Sakshi, Sethi, Jing, Zhao
Publikováno v:
Leukemia & Lymphoma. 64:339-348
Chimeric antigen receptor T-cell (CAR-T) infusion settings may impact healthcare resource use (HRU) and reimbursement amounts. Adults with diffuse large B-cell lymphoma receiving CAR-T therapy were identified from the Centers for MedicareMedicaid Ser
Autor:
Richard T. Maziarz, Hongbo Yang, Qing Liu, Travis Wang, Jing Zhao, Stephen Lim, Soyon Lee, Anand Dalal, Vamsi Bollu
Publikováno v:
Leukemia & Lymphoma. 63:2052-2062
This study compared the real-world healthcare resource utilization (HRU), costs, adverse events (AEs), and AE treatments associated with the chimeric antigen receptor T-cell (CAR-T) therapies, tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (
Autor:
Nathan H. Fowler, Michael Dickinson, Monalisa Ghosh, Andy I. Chen, Charalambos Andreadis, Ranjan Tiwari, Aisha Masood, Roberto Ramos, Vamsi Bollu, Etienne Jousseaume, Catherine Thieblemont, Martin Dreyling, Stephen J. Schuster
Publikováno v:
Transplantation and Cellular Therapy. 28:S170-S171
Autor:
Leslie Popplewell, Charalambos Andreadis, Catherine Thieblemont, Andrés J.M. Ferreri, Hideo Harigae, Arne Kolstad, Phoebe Joy Ho, Fritz Offner, Aisha Masood, Ranjan Tiwari, Jie Zhang, Piers Em Patten, Jose Antonio Pérez Simón, L. J. Nastoupil, Kouji Kato, Stephen J. Schuster, M. Dreyling, Takanori Teshima, Ram Malladi, Andreas L. Petzer, Bastian von Tresckow, Monalisa Ghosh, Nathan Fowler, Joseph P. McGuirk, Peter A. Riedell, Joaquin Martinez-Lopez, Jason Butler, P. L. Zinzani, Andreas Viardot, Emmanuel Bachy, M. José Kersten, Michael Dickinson, Julio C. Chavez, Vamsi Bollu
Publikováno v:
Hematological Oncology. 39
Autor:
Hongbo Yang, Abhijit Agarwal, David Kuzan, Marcela Martinez-Prieto, Vamsi Bollu, Wenxi Tang, Marie-Jose Kersten, Richard T. Maziarz, Stephen J. Schuster, Jie Zhang
Publikováno v:
Hematological Oncology. 39
Publikováno v:
Clinical therapeutics. 43(8)
Purpose To assess the cost-effectiveness and cost-effective price of tisagenlecleucel, a novel, effective chimeric antigen receptor T-cell therapy, versus salvage chemotherapy (SC) for the treatment of relapsed or refractory diffuse large B-cell lymp
Autor:
Stephen J. Schuster, Jie Zhang, Hongbo Yang, Abhijit Agarwal, Wenxi Tang, Marcela Martinez-Prieto, Vamsi Bollu, David Kuzan, Richard T. Maziarz, Marie José Kersten
Publikováno v:
Leukemia & lymphoma. Informa Healthcare
Leukemia and Lymphoma, 63(4), 845-854. Informa Healthcare
Schuster, S J, Zhang, J, Yang, H, Agarwal, A, Tang, W, Martinez-Prieto, M, Bollu, V, Kuzan, D, Maziarz, R T & Kersten, M J 2022, ' Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas : an indirect treatment comparison ', Leukemia and Lymphoma, vol. 63, no. 4, pp. 845-854 . https://doi.org/10.1080/10428194.2021.2010069
Leukemia and Lymphoma, 63(4), 845-854. Informa Healthcare
Schuster, S J, Zhang, J, Yang, H, Agarwal, A, Tang, W, Martinez-Prieto, M, Bollu, V, Kuzan, D, Maziarz, R T & Kersten, M J 2022, ' Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas : an indirect treatment comparison ', Leukemia and Lymphoma, vol. 63, no. 4, pp. 845-854 . https://doi.org/10.1080/10428194.2021.2010069
This study compared overall survival (OS), progression-free survival (PFS), complete response rate (CRR), and overall response rate (ORR) of tisagenlecleucel (tisa-cel) and lisocabtagene maraleucel (liso-cel) in relapsed or refractory large B-cell ly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f91da64d2502024148cdecb9e24326e
https://pure.amc.nl/en/publications/comparative-efficacy-of-tisagenlecleucel-and-lisocabtagene-maraleucel-among-adults-with-relapsedrefractory-large-bcell-lymphomas(61ae7c8d-3442-49a9-a3da-bbedaa31280b).html
https://pure.amc.nl/en/publications/comparative-efficacy-of-tisagenlecleucel-and-lisocabtagene-maraleucel-among-adults-with-relapsedrefractory-large-bcell-lymphomas(61ae7c8d-3442-49a9-a3da-bbedaa31280b).html
Autor:
Vamsi Bollu, Nicola A. Hanania, James F. Donohue, Lauren Nelson, Michael D Stensland, Valerie Williams, Donald E. Stull
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease
James F Donohue,1 Vamsi K Bollu,2 Donald E Stull,3 Lauren M Nelson,4 Valerie SL Williams,4 Michael D Stensland,5 Nicola A Hanania6 1Department of Pulmonary Diseases and Critical Care Medicine, The University of North Carolina at Chapel Hill, Chapel H
Autor:
Monalisa Ghosh, Ranjan Tiwari, Catherine Thieblemont, Andy I. Chen, Roberto Ramos, Vamsi Bollu, Etienne Jousseaume, Martin Dreyling, Michael Dickinson, Stephen J. Schuster, Charalambos Andreadis, Aisha Masood, Nathan Fowler
Publikováno v:
Blood. 138:3533-3533
Background: Follicular lymphoma (FL) is the second most frequently diagnosed Non-Hodgkin lymphoma subtype in Western countries. Patients often undergo multiple lines of therapy over many years throughout the course of their disease with worse surviva